This Medudy course is a conference report for physicians on the topic “SGO 2026 – Annual Conference on Women’s Cancers.”
Prof. Dr. Fabian Trillsch, Deputy Director of the Department of Obstetrics and Gynecology at LMU Medical Center in Munich, will summarize key highlights from the studies presented at the conference.
The final results regarding overall survival from the Phase III ROSELLA study will be presented, which compared a combination of relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in platinum-resistant ovarian cancer; the first results from the Phase III NRG-GY019 study evaluating the non-inferiority of first-line letrozole versus paclitaxel plus carboplatin followed by letrozole in low-grade serous ovarianor peritoneal carcinoma, and the results of the Phase II GOG 3039 study, which evaluated the efficacy and safety of abemaciclib in combination with letrozole in advanced or recurrent endometrioid endometrial carcinoma.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
By the end of this conference report, you will know:
- Some of the highlights of the 2026 SGO Annual Meeting
- The most important takeaways from the studies presented
- The expert's conclusion on the studies presented
